Dana Yaacov-Garbeli - Jul 16, 2025 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Signature
/s/ Dana Yaacov-Garbeli
Stock symbol
ENTX
Transactions as of
Jul 16, 2025
Transactions value $
$0
Form type
4
Date filed
7/18/2025, 04:34 PM
Previous filing
Apr 23, 2024

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Yaacov-Garbeli Dana Chief Financial Officer KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, ISRAEL /s/ Dana Yaacov-Garbeli 2025-07-18 0001909822

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTX Ordinary Shares, par value NIS 0.0000769 per share Award $0 +26.3K +30.34% $0.00 113K Jul 16, 2025 By A2Z Counseling Ltd. F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTX Stock Option (right to buy) Award $0 +130K $0.00 130K Jul 16, 2025 Ordinary Shares, par value NIS 0.0000769 per share 130K $2.28 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.
F2 These shares are owned by A2Z Counseling Ltd. of which the reporting person owns a 33.33% interest and has effective control over voting and disposition of the shares. The reporting person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3 This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.